Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial
Diabetic Medicine, 10/01/09
Bansal D et al. – As there are few differences between the two treatments in efficacy, pregabalin 150 mg twice daily might be the alternative choice as it is associated with fewer adverse effects in this population.
Methods- A randomized, double–blind, crossover, active–control, clinical trial with variable dose titration was carried out (n = 51).
- Amitriptyline orally, at doses of 10, 25 and 50 mg at night–time and pregabalin orally, at doses of 75, 150 and 300 mg twice daily, by optional titration was used.
- Each drug treatment was of 5 weeks.
- There was a placebo washout period for 3 weeks between the two drugs. Assessment for pain relief, overall improvement and adverse events were carried out.
- Good, moderate and mild pain relief were noted in 21 (48%), 6 (13%) and 7 (15%) patients on pregabalin and 15 (34%), 5 (11%) and 12 (27%) patients on amitriptyline, respectively, by patient's global assessment of efficacy and safety.
- Patient and physician's global assessment, McGill pain questionnaire, Likert pain scale and Patient Global Impression of Change showed no significant difference between the treatments, although improvement with both treatments was seen from the first week.
- Of the 52 adverse events reported, 34 (65.4%) were with amitriptyline, drowsiness being the commonest [in 19 (43%) patients]. Pregabalin caused adverse events in 18 (25%), of which drowsiness was the most common in nine (20%) patients.
- The preferred pregabalin dose was 150 mg twice daily.
Related Articles
Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington State
Journal of Opioid Management, 11/03/09
Relevance Score: 82%
Prevalence and impact of pain in diabetic neuropathy
European Diabetes Nursing, 10/21/09
Relevance Score: 82%
New diagnostic tests for diabetic distal symmetric polyneuropathy
Journal of Diabetes and its Complications, 11/13/09
Relevance Score: 81%
A Randomized Clinical Trial of the Effectiveness of Photon Stimulation on Pain, Sensation, and Quality of Life in Patients With Diabetic Peripheral Neuropathy
Journal of Pain and Symptom Management, 11/09/09
Relevance Score: 81%
Duloxetine for treating painful neuropathy or chronic pain
Cochrane Reviews, 10/08/09
Relevance Score: 81%
Today in Neuropathy/Myopathy...keeping you current
Receive free subspecialty "5-minute updates" via email
Copper Deficiency Myeloneuropathy Due to Occult Celiac Disease
The Neurologist, 11/20/09
Autoimmune Polyglandular Syndrome Type 2 With Myasthenia Gravis Crisis
The Neurologist, 11/20/09
Sarcomeric alpha-actinins and their role in human muscle disease
Future Neurology, 11/20/09
Today in Pain Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Treatment of pathologic spinal fractures with combined radiofrequency ablation and balloon kyphoplasty
World Journal of Surgical Oncology, 11/20/09
When should you consider implanted nerve stimulators for lower back pain?
APCToday, 11/20/09
Guidelines for the proper use of epidural steroid injections for the chronic pain patient
Techniques in Regional Anesthesia and Pain Management, 11/20/09
Sponsor
Article Search
Sponsor


See Latest Articles


